Table 1 In vitro and in vivo studies of non-nucleotide based STAT inhibitors

Stattic (20, 31, 40, 42)

Breast (MDA-MB-231, -435S,-468, SUM159, SK-BR-3), Hepatocellular (SNU-387, -398, -449, Hep3B HepG2, Huh-7), Pancreatic (Panc-1, HPAC, BXPC-3, SW1990), Colon (SW480, HCT-116), Glioblastoma (U87, U251), Multiple Myeloma (U266, ARH77)

STA-21 (22, 23)

Rhabdomyosarcoma (RH30, RD2), Breast (MDA-MB-231, -435 s, -468)

LLL-3 (24,25)

Glioblastoma (U87, U251, U373), Chronic Myeloid Leukemia (K562), Prostate (DU145)

Glioblastoma (U87)

LLL12 (26–29, 46–47)

Medulloblastoma (Daoy, UW426, UW288-1), Glioblastoma (U87, U87delta, U373), Multiple Myeloma (U266, ARH-77 & patient’s primary cell lines), Breast (MDA-MB-231, SK-BR3), Pancreatic (HPAC, Panc-1), Rhabdomyosarcoma lines (RD2, RH28, RH30), Osteosarcoma (U2OS, SAOS2, SJSA)

Multiple Myeloma (ARH-77), Glioblastoma (U87), Breast (MDA-MB-231), Osteosarcoma (OS33)

XZH-5 (29–31)

Rhabdomyosarcoma (RD2, RH30, RH28), Breast (MDA-MB-231, SUM 159), Pancreatic (Panc-1, SW 1990), Hepatocellular (SNU-387, SNU-398, HepG2, Huh-7)

S31-201 (32, 40)

Breast (MDA-MB-231, -435, -468), Multiple Myeloma (U266, ARH77)

Breast (MDA-MB-231)

SF-1066 (33,34)

Breast (MDA-MB-231, -468); Pancreatic (Panc-1), Prostate (DU145), Acute Myeloid Leukemia (OCI-AML-2)

Breast (MDA-MB-231)

SF-1087 (33)

Breast (MDA-MB-468), AML (OCI-AML-2), Prostate (DU145)

17o (35)

Breast (MDA-MB-468), Prostate (DU145), Multiple Myeloma (JJN3)

Cryptotanshinone (37)

Prostate (DU145), Breast (MDA-MB-468)

FLL32 (40, 42, 44, 45, 46, 47)

Rhabdomyosarcoma (RD2, RH28, RH30); Renal (ACHN, SK-RC-45, -54, Caki), Melanoma (A375, Hs294T), HN-SCC (UM-SCC-29, -74B), Breast (MDA-MB-231,-468, SUM159, SK-BR-3), Pancreatic (Panc-1, HPAC, BXPC-3, SW1990); Colon (SW480, HCT-116), Glioblastoma (U87, U251), Multiple Myeloma (U266, ARH77), Hepatocellular (SNU-449, SNU-398, SNU-387, Hep3B), Osteosarcoma (U2OS, SAOS2, SJSA)

Breast (MDA-MB-231), Osteosarcoma (OS33), Pancreatic^* (Panc-1 in chicken embryo chorioallontoic membrane)

FLL62 (45)

Renal cell carcinoma (ACHN, SK-RC-45, SK-RC-54, Caki), Melanoma (A375, Hs294T)

C188-9 (49)

Acute Myeloid Leukemia (Kasumi-1, THP-1, GDM-1, NB-4)

LY5 (50)

Osteosarcoma (U2OS), Rhabdosarcoma (RH30, RD2), Ewing Sarcoma (EW8).

Breast (MDA-MB-231)

BP-1108 & BP-1075 (52)

Chronic Myeloid Leukemia (K562) and Acute Myeloid Leukemia (MV4-11)

IS3 295 (54)

Breast (MDA-MB-231,-435,-468), Prostate (DU145), Pancreatic (Panc-1), MM (U266)

Galiellalactone (55)

Prostate cancer (DU145, PC-3)

Prostate (DU145)

JQ1 (58)

T cell –Acute Lymphoblastic Leukemia